ONVO vs. BCDA, GENE, PHXM, EIGR, CELZ, TCON, CHRO, TTNP, COEP, and MBOT
Should you be buying Organovo stock or one of its competitors? The main competitors of Organovo include BioCardia (BCDA), Genetic Technologies (GENE), PHAXIAM Therapeutics (PHXM), Eiger BioPharmaceuticals (EIGR), Creative Medical Technology (CELZ), TRACON Pharmaceuticals (TCON), Chromocell Therapeutics (CHRO), Titan Pharmaceuticals (TTNP), Coeptis Therapeutics (COEP), and Microbot Medical (MBOT). These companies are all part of the "medical" sector.
Organovo (NASDAQ:ONVO) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation, dividends and community ranking.
BioCardia has higher revenue and earnings than Organovo. BioCardia is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks.
Organovo received 186 more outperform votes than BioCardia when rated by MarketBeat users. Likewise, 51.31% of users gave Organovo an outperform vote while only 47.62% of users gave BioCardia an outperform vote.
BioCardia has a net margin of -2,197.72% compared to Organovo's net margin of -4,061.12%. Organovo's return on equity of -182.88% beat BioCardia's return on equity.
Organovo has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.
9.1% of Organovo shares are held by institutional investors. Comparatively, 16.5% of BioCardia shares are held by institutional investors. 4.0% of Organovo shares are held by company insiders. Comparatively, 23.9% of BioCardia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, BioCardia had 4 more articles in the media than Organovo. MarketBeat recorded 6 mentions for BioCardia and 2 mentions for Organovo. Organovo's average media sentiment score of 0.96 beat BioCardia's score of 0.17 indicating that Organovo is being referred to more favorably in the media.
BioCardia has a consensus price target of $4.00, indicating a potential upside of 935.46%. Given BioCardia's higher possible upside, analysts clearly believe BioCardia is more favorable than Organovo.
Summary
BioCardia beats Organovo on 10 of the 17 factors compared between the two stocks.
Get Organovo News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Organovo Competitors List
Related Companies and Tools